- Home
- / HLS Therapeutics
HLS Therapeutics
Stock Price
$3.5
2024-10-29
Market Capitalization
$110.3 M
2024-10-29
Revenue
$55.5 M
FY, 2025
HLS Therapeutics Summary
Company Summary
- Overview
- HLS Therapeutics is a specialty pharmaceutical company dedicating itself to acquiring and distributing commercial-stage mature, or legacy, branded pharmaceutical drugs. It focuses on products targeting the central nervous system and cardiovascular therapeutic areas.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Toronto, CA | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Ryan C. Lennox, Senior Vice-President, Legal, Human Resources and Compliance – BA, JD
Patricia Perry, Vice-President Human Resource
Jason A. Gross, Vice-President Scientific Affairs
LocationsView all
4 locations detected
Toronto, ON HQ
Canada
10 Carlson Ct #701, Etobicoke
Bryn Mawr, PA
United States
919 Conestoga Rd
Mount Laurel Township, NJ
United States
East Gate Center, 309 Fellowship Rd STE 200
Winnipeg, MB
Canada
1375 Trans-Canada Hwy #610
HLS Therapeutics Financials
Summary Financials
- Revenue (FY, 2025)
- $55.5M
- Gross profit (FY, 2025)
- $45.4M
- Net income (FY, 2025)
- ($12.4M)
- Cash (FY, 2025)
- $11.7M
- EBIT (FY, 2025)
- ($5.5M)
- Enterprise value
- $143.5M